Results 121 to 130 of about 77,701 (209)

Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT? [PDF]

, 2001
McMurray, John J.V.
core   +1 more source

Drug-drug interactions in repeat prescriptions at village dispensaries (bereg) in Malta [PDF]

, 2013
Inappropriate treatments and drug-drug interactions (DDIs) are known to occur in settings where repeat prescriptions are issued. In view of this, a study was carried out to document any such problematic drug prescribing and propose changes that would
Bugeja, Anton
core  

Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer

Oncology Reviews, 2011
Angiotensin II (Ang-II) plays a key role as a vasoconstrictor in controlling blood pressure and electrolyte/fluid homeostasis. Recently it has also been shown that this peptide is a cytokine, acting as a growth factor in cardiovascular and stromal cells.
Hiroji Uemura, Hitoshi Ishiguro, Yoshinobu Kubota   +2 more
doaj   +2 more sources

Valsartan in the treatment of heart attack survivors

Vascular Health and Risk Management, 2006
Bodh I JugduttDivision of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, CanadaAbstract: Survivors of myocardial infarction (MI) are at high risk of disability and death. This is due to infarct-related complications such as
Bodh I Jugdutt
doaj  

Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction. [PDF]

Korean J Intern Med, 2016
Lee JH, Bae MH, Yang DH, Park HS, Cho Y, Lee WK, Jeong MH, Kim YJ, Cho MC, Kim CJ, Chae SC, Korea Acute Myocardial Infarction Registry Investigators.   +11 more
europepmc   +1 more source

Management of Proteinuria in Dogs and Cats with Chronic Kidney Disease [PDF]

, 2016
Atkins, Bakris, Bianchi, Bomback, Brown, Brown, Brown, Brown, Bugbee, Christ, Finco, Grauer, Grauer, Horita, Jacob, Jenkins, Jepson, Jepson, Jonathan Elliott, King, King, Laverman, Lees, Lefebvre, LeVine, Linas, Littman, Maack, McAlister, Mizutani, Nabity, Nakamura, Pollock, Pressler, Ryan, Schjoedt, Schneider, Segev, Segev, Sent, Shelly L. Vaden, Singh, Syme, Tenhundfeld, Toblli, Vaden, Wehner   +46 more
core   +2 more sources

Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults. [PDF]

Cochrane Database Syst Rev, 2016
Zou Z, Yuan HB, Yang B, Xu F, Chen XY, Liu GJ, Shi XY.   +6 more
europepmc   +1 more source

Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers

Drug, Healthcare and Patient Safety, 2010
Elisabet Ekman1, Staffan Hägg2, Anders Sundström3, Viktoria Werkström11Regional Pharmacovigilance Unit, Clinical Pharmacology, Lund University Hospital, Lund, Sweden; 2Division of Clinical Pharmacology, Linköping ...
Elisabet Ekman, Staffan Hägg, Anders Sundström, et al   +3 more
doaj  

Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC. [PDF]

Sci Rep, 2016
Miao L, Chen W, Zhou L, Wan H, Gao B, Feng Y.   +5 more
europepmc   +1 more source

A Retrospective Analysis of Human Angiotensin II Receptor Blockers (ARB) Pharmacokinetics, Dosages and C_max Values for the Experimental Modelling of Pleiotropic and Supratherapeutic Activities. [PDF]

Basic Clin Pharmacol Toxicol
Evans A, Bernatchez P.
europepmc   +1 more source